Ramin Khoramnia (University Eye Clinic Heidelberg, Heidelberg, Germany) discusses imitations of current treatment options for neovascular age-related macular degeneration, gives an overview of faricimab, its dosing regimen and its mechanism of action and discusses the major efficacy and safety findings of the STAIRWAY study, which were presented at WOC 2020.
1. What are the limitations of current treatment options for neovascular age-related macular degeneration? (0:05)
2. Could you give us an overview of faricimab, its dosing regimen and its mechanism of action? (1:07)
3. What were the aims and design of the STAIRWAY study? (2:07)
4. What were the major efficacy and safety findings of this study? (2:54)
5. What is the potential for combining faricimab with angiopoietin-2 and vascular endothelial growth factor inhibitors and what future studies are planned? (3:33)
Disclosures: Ramin Khoramnia has received grant support from: Alimera, Bayer, Chengdu Kanghong, Novartis, and Roche; travel support from: Alimera, Allergan, Bayer, Novartis, and Roche; and lecture fees from: Alimera, Allergan, Bayer, Novartis, and Roche.
touchOPHTHALMOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and funded by Touch Medical Media
Published: 31 July 2020
Share this Video
Related Videos In Macular Degeneration
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Rahul Khurana, AAO 2022: Loss to follow-up in patients with nAMD treated with anti-VEGF therapy in the US
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 1
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a study investigating the relationship between OCTA and fluorescein angiography/indocyanine green angiography in AMD. ‘Morphological and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!